Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness

Slide: 15 of 34

Triple Therapy Containing Telaprevir Versus Dual Therapy for Patients With HCV Genotype 1 Infection (2 of 2)

One trial of 1,088 patients with HCV genotype 1 infection using response-guided triple therapy with telaprevir (12 weeks of pegylated interferon alfa-2a, ribavirin, and telaprevir) plus response-guided dual therapy (the next 12–36 weeks) versus dual therapy with pegylated interferon alfa-2a plus ribavirin (48 weeks) found no clear differences in relative risk estimates in patients stratified by age, sex, race, baseline fibrosis status, or body mass index.

Absolute sustained virologic response (SVR) rates were higher in patients younger than 45 years versus those older than 45 years (83% vs. 70%) and in patients of white race versus patients of black race (75% vs. 62%). The strength of evidence for this finding was rated moderate. Absolute SVR rates were also higher in patients with no or minimal fibrosis versus those with advanced fibrosis or cirrhosis (81% vs. 62%), and those with a body mass index <25 versus those with a higher body mass index (83% vs. 69%). The strength of evidence for this finding was rated low.